Merck enters exclusive global license agreement with Scibrunch Therapeutics for SPR2015
MRK•Merck entered an exclusive global license agreement with Scibrunch Therapeutics for SPR2015, an investigational oral KRAS G12D (ON) inhibitor. The deal includes $400 million upfront and has a total potential value of $2.13 billion; Merck will record a $400 million pretax charge, or $0.13 per share, in Q3 2026.
1. License agreement
Merck said the deal closed and grants it exclusive worldwide rights to develop, manufacture and commercialize SPR2015.
2. Deal costs
The agreement includes $400 million upfront and has a total potential value of $2.13 billion. Merck said it will record a $400 million pretax charge, equal to $0.13 per share, in Q3 2026.
